Background: Paragangliomas are neoplasms arising from extraadrenal chromaffin cells. In the trachea, these tumors are exceedingly rare and only a few cases have been reported in the medical literature. Tracheal paragangliomas usually present with hemoptysis.

Case report: This report describes a 32 year old Moroccan man suffering from progressive dyspnea and hemoptysis due to tracheal tumor. Histopathology of tumor after surgery showed paraganglioma. A circular resection of the trachea carrying the first 4 rings allowed for resecting the entire tumor. No recurrence of tumor was detected at bronchoscopy six months later and it demonstrated good healing of the anastomosis.

Conclusion: Paraganglioma is an unusual histology for tracheal neoplasms. The originality of this case lies in the rarity of this type of tumor, tracheal location that is even more rare and differential diagnostic problem which arises. Clinical features, histological appearance and differential diagnosis as well as treatment are discussed

Lactose Intolerance (LI) is a natural process where production of lactase, an intestinal disaccharide, decreases during the aging due to lack of consumption. There are several sub-types of lactose tolerance: Lactose Tolerant (LT), Lactose Intolerant (LI) and Lactose Mal-absorber (LM). Osteoporosis (OP) is a degenerative endocrinal bone disorder affecting over 200 million people worldwide whereas LI affects up to 70% of the world’s population and approximately 15% of the UK population. OP develops predominantly with age and affects mainly women due to hormonal imbalance post-menopause which when coupled with lack of dairy intake, a key source of lactase and calcium required for bone ossification, leads to the increased bone loss. Understanding the association between LI and OP can lead to better prognosis, prevention technique and treatment.

A young Asian woman was treated for metastasized adenocarcinoma of the lung. Diagnostic evaluation identified a mutation in the Epidermal Growth Factor Receptor (EGFR) gene as well as a mutation in breast cancer 2 (BRCA2). Response to treatment was seen using radiographic imaging and in plasma Circulating Tumor DNA (ctDNA) levels of the BRCA2 and EGFR mutations.

Background: Malignant pleural effusion is a common problem in patients with advanced malignancies and compromised the short-lived survival of these patients. These effusions can be resistant to the treatment such as systemic chemotherapy, pleurodesis with sclerosantagents and recurrent drainage. Therefore, new therapeutic options are needed. The purpose of this study was to evaluate the effectiveness of intrapleural chemotherapy with Cisplatin for the management of MPE in lung, breast and mesothelioma cancers.

Materials and methods: Twenty-one cancer patients with MPE were enrolled in this study. Cisplatin was injected through a catheter at a dose of 30mg /m2, and this procedure was performed 3 times at intervals of two weeks. Patients were evaluated for side effects and responses to the treatment every two weeks and one month after the last treatment.

Results: Among the assessable 18 patients, complete response and partial response were 9 (50%) and 4 (22.2%) patients, respectively (overall response rate 72.2%). Dyspnea was improved in 13 (72.2%) patients and had no change in 5 (27.8%) patients. One patient did not refer after the first intrapleural injection. Also two patients died during the study. None of the patients had side effects of grade 3 and 4.

Conclusion: The results of this trial study showed that using of Intrapleural Chemotherapy with cisplatin in the management of patients with MPE in lung, breast and mesothelioma cancers is effective and safe.